Trial Profile

Drug Use-Results Survey of OPDIVO [unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy]

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Gastric cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Ono Pharmaceutical

Most Recent Events

18 Oct 2022 Status changed from active, no longer recruiting to completed.
21 Sep 2020 Results assessing nivolumab safety data of 650 patients, presented at the 45th European Society for Medical Oncology Congress.
01 Oct 2018 Status has been changed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com